Equities Analysts Set Expectations for RDY FY2026 Earnings

Dr. Reddy’s Laboratories Limited (NYSE:RDY) – Analysts at Zacks Research lowered their FY2026 earnings estimates for Dr. Reddy’s Laboratories in a research note issued on Wednesday, February 12th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.79 per share for the year, down from their previous forecast of $0.80. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2026 earnings at $0.19 EPS and Q2 2027 earnings at $0.15 EPS.

Other equities research analysts have also issued reports about the stock. Barclays lowered their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 6th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Finally, Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th.

Dr. Reddy’s Laboratories Trading Down 2.8 %

Shares of Dr. Reddy’s Laboratories stock opened at $13.60 on Friday. Dr. Reddy’s Laboratories has a 1 year low of $13.36 and a 1 year high of $16.89. The firm has a market cap of $11.35 billion, a PE ratio of 21.65 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.38. The company has a 50 day simple moving average of $14.73 and a two-hundred day simple moving average of $15.29.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%.

Institutional Trading of Dr. Reddy’s Laboratories

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Robeco Institutional Asset Management B.V. grew its position in shares of Dr. Reddy’s Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock worth $180,620,000 after buying an additional 9,373,412 shares during the period. Renaissance Technologies LLC boosted its stake in Dr. Reddy’s Laboratories by 382.9% in the 4th quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company’s stock worth $148,717,000 after purchasing an additional 7,467,979 shares in the last quarter. Aikya Investment Management Ltd boosted its stake in Dr. Reddy’s Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company’s stock worth $88,590,000 after purchasing an additional 4,523,303 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Dr. Reddy’s Laboratories by 405.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company’s stock worth $84,643,000 after purchasing an additional 4,301,212 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Dr. Reddy’s Laboratories by 397.2% in the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock worth $77,311,000 after purchasing an additional 3,911,404 shares in the last quarter. 3.85% of the stock is owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.